Allarity Therapeutics(ALLR) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights - Cash balance at $18.5 million - Strengthened leadership team with new members driving stenoparib development - NASDAQ compliance regained Boston (November 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selectio ...